title: Incidence of immunoglobulin G antibodies to Chlamydia pneumoniae in acute myocardial infarction patients.
abstract: BACKGROUND
  Recent studies have suggested a possible association between Chlamydia pneumoniae infection and coronary heart disease.
  
  
  OBJECTIVE
  To determine titers of antibodies to C. pneumoniae in patients with acute myocardial infarction compared with titers in several control groups.
  
  
  METHODS
  This prospective case-control study investigated 209 individuals. We assessed the serum IgG antibody titers to C. pneumoniae in 57 consecutive patients admitted with AMI to our intensive coronary care unit during a 4 month period. A serum sample was drawn upon admission and after 6 weeks. Results were compared with those of four control groups: a) patients admitted with community-acquired pneumonia (n = 18), b) patients with community-acquired urinary tract infection (n = 42), c) patients with angiographically normal coronary artery disease (n = 44), and d) patients with stable coronary artery disease (n = 48). Serum immunoglobulin G antibody titers to C. pneumoniae were determined using standard micro-immunofluorescence technology.
  
  
  RESULTS
  Of 57 patients with AMI, 32 (56%) had a high IgG titer to C. pneumoniae (> or = 1:256) on the initial test, which remained unchanged (62%) after 6 weeks. The percentage of patients with high titers was significantly lower in the control groups: 5 of 18 patients (28%) in the pneumonia group (P < 0.01), 11 of 42 (26%) in the urinary tract infection group (P < 0.01), 11 of 44 (25%) with normal coronary arteries (P < 0.01), and 17 of 48 (35%) with stable chronic ischemic heart disease (P < 0.05).
  
  
  CONCLUSIONS
  The detection of high titers of IgG antibodies to C. pneumonia in many patients with AMI, compared to control groups, suggests that chronic Chlamydia pneumoniae infection plays a role in the pathogenesis of atherosclerosis and acute ischemic events.
authors.affiliation: Infectious Diseases Unit, Shaare Zedek Medical Center, Jerusalem, Israel.
authors.forename: H
authors.initials: H
authors.lastname: Ashkenazi
authors.forename: B
authors.initials: B
authors.lastname: Rudensky
authors.forename: E
authors.initials: E
authors.lastname: Paz
authors.forename: D
authors.initials: D
authors.lastname: Raveh
authors.forename: J A
authors.initials: JA
authors.lastname: Balkin
authors.forename: D
authors.initials: D
authors.lastname: Tzivoni
authors.forename: A M
authors.initials: AM
authors.lastname: Yinnon
mesh_terms: D000906:Antibodies / Q000097:blood* / Q000276:immunology; D016022:Case-Control Studies; D023521:Chlamydophila Infections / Q000097:blood* / Q000453:epidemiology* / Q000276:immunology; D016993:Chlamydophila pneumoniae / Q000276:immunology*; D003325:Coronary Care Units; D005260:Female; D005455:Fluorescent Antibody Technique; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood* / Q000276:immunology; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000453:epidemiology* / Q000276:immunology; D011446:Prospective Studies; D016036:Seroepidemiologic Studies
chemical_list: D000906:Antibodies; D007074:Immunoglobulin G